Ateneo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ateneo

Quick Facts

Property Description
Active ingredient Atenolol
Form Oral Tablet
Pharmacological class beta-Adrenergic Receptor Antagonist (Beta-blocker)
Primary action Decreases heart rate and myocardial contractility
Origin Synthetic compound

Atenolol: Classification and Active Component

Ateneo is a commercial drug preparation whose sole active pharmaceutical ingredient is Atenolol, a foundational molecule in cardiovascular pharmacology. This synthetic compound is scientifically classified as a beta-Adrenergic Receptor Antagonist, widely known as a beta-blocker. Atenolol is specifically categorized as a second-generation beta1-selective adrenergic antagonist, a feature clinically recognized for its targeted action predominantly on the beta1-receptors found in the heart tissue. This selectivity differentiates it from non-selective beta-blockers, establishing its place within modern pharmacological guidelines. The drug entity is typically presented for patient use as an oral tablet and is characterized as a single-ingredient product, although combination formulations do exist.

Physical Form and General Therapeutic Purpose

The general therapeutic purpose of this medication is directly derived from its pharmacological class. As a beta1-selective antagonist, Atenolol's mechanism reduces the effects of stimulatory stress hormones, such as adrenaline, on the heart. This mitigation leads to a decreased heart rate and a reduction in myocardial contractility, thereby lowering the overall workload and oxygen demand of the heart muscle. Consequently, the medication serves as a foundational Antihypertensive agent and Antianginal drug that is broadly used to support cardiovascular stability. It is clinically recognized for its effectiveness in stabilizing heart rhythm and assisting in the maintenance of healthy blood pressure levels. The oral tablet form facilitates a convenient route of administration for chronic cardiovascular management.

Regulatory References

  1. NIH StatPearls
  2. NIH DailyMed

What side effects are possible with Ateneo?

Possible Side Effects and Safety Information

Regulatory documents organize the possible adverse effects of Atenolol (Ateneo) according to frequency and the body system affected. Officially documented common adverse reactions (affecting 1 to 10 users in 100) include fatigue, cold extremities, and a decrease in heart rate, known as bradycardia, alongside general gastrointestinal disturbances. Uncommon effects (0.1–1%) generally relate to psychiatric and liver functions, such as sleep disturbances, mood changes, and raised levels of transaminases.

Rare effects (0.01–0.1%) span multiple system-organ classes, including dizziness, headache, visual disturbances, dry eyes, and dermatological concerns like alopecia and skin rashes. Serious adverse reactions listed in official labeling include the potential for the deterioration of heart failure, the precipitation of heart block, or episodes of bronchospasm, particularly in individuals with pre-existing conditions.

Special Safety Considerations are defined for specific groups. The official label notes that use in the pediatric population is not recommended due to insufficient safety data. Furthermore, special monitoring is required for older adults and those with renal impairment because the medication's elimination rate is affected by kidney function.

Safety Constraints (Contraindications)

Official regulatory documents establish strict limitations on use (contraindications). The medication should not be used in patients presenting with severe sinus bradycardia, second- or third-degree heart block, cardiogenic shock, overt cardiac failure, metabolic acidosis, or untreated pheochromocytoma.

Additionally, a specific safety pattern concerning exposure duration is documented: abrupt discontinuation, especially in individuals with pre-existing heart disease, may be associated with the exacerbation of chest pain or other severe cardiac events.

Overdose and Emergency Response

A suspected overdose of Ateneo (Atenolol) is a severe medical event recognized by regulatory authorities as a potentially life-threatening scenario that requires immediate, urgent attention. Contact emergency services immediately if a person who has taken an overdose is experiencing collapse, seizures, severe difficulty breathing, or cannot be awakened. For less severe concerns, official guidance directs contact with the Poison Control helpline for assistance.

Overdose manifestations are primarily characterized by severe physiological suppression. Documented presentations include profound bradycardia (slow heart rate), severe hypotension (low blood pressure), and lethargy. The official profile also lists the potential for more severe outcomes such as heart block, acute cardiac failure, bronchospasm, and systemic effects like hypoglycemia (low blood sugar).

Due to the drug's elimination route, patients with impaired renal function may experience an increased risk of drug accumulation and toxicity during an overdose scenario. In the hospital setting, supportive care is provided, which may include procedures for removing unabsorbed drug, such as gastric lavage or activated charcoal. Specific agents like Atropine and Glucagon may be administered to counteract severe cardiac effects, and hemodialysis is documented as a method to help remove the drug from the body.

Therapeutic Uses of Ateneo

What Ateneo Treats: Main Uses and Benefits

The medication is commonly used across domains involving significant cardiovascular risk and heightened physiological activity. It plays a role in managing conditions characterized by periods of heightened symptoms that interfere with daily functioning.

This medication is applied in conditions where the heart’s workload needs stabilization. Primary uses include addressing Hypertension (high blood pressure), managing Angina Pectoris (chest pain), and addressing Cardiac Dysrhythmias involving an overly rapid or irregular heartbeat. The medication may assist with providing supportive relief for symptoms related to systemic imbalance and cardiovascular stress.

“This approach helps address symptom clusters that may become intense or disruptive, especially during periods of activity.”

This supportive role is generally relevant for easing the overall symptom load and contributes to improved comfort during periods of heightened symptoms. The therapeutic scope also extends to specific non-cardiac symptom patterns, where it is used for the preventive treatment of recurrent symptoms such as migraine headaches, and the control of physical manifestations like essential tremor.

Quick Fact: Relief for Heightened Symptoms
Primary Focus Management of conditions marked by increased physiological stress.
Symptom Management Easing chest pain, stabilizing rapid heart rate and palpitations.
Patient Benefit May assist with maintaining functional stability and easing overall symptom burden.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed service

Eligibility and Restrictions for Use

Who Can and Cannot Use Ateneo?

Eligibility for Ateneo (Atenolol) is strictly determined by official regulatory labeling, focusing on specific health conditions and demographic factors.

Contraindications and Prohibited Use

Use of this medicine is absolutely contraindicated (prohibited) for patients with several serious cardiovascular conditions, including cardiogenic shock, overt or uncontrolled heart failure, second or third-degree heart block, and significant sinus bradycardia (very slow heart rate). The label also prohibits use in cases of severe bronchial asthma or severe COPD (bronchial hyperresponsiveness), metabolic acidosis, and untreated phaeochromocytoma.

Population Group Eligibility Status
Adults (18+ years) Eligible for labeled indications.
Pediatric Patients Not established and not recommended (under 18 years).
Renal Impairment Conditional; requires mandatory dosage reduction for eligibility.
Pregnancy/Lactation Use requires caution due to documented risks.

Condition-Based Restrictions

Patients with renal impairment must have their dosage reduced to maintain eligibility. Use requires specific caution and monitoring in older adults, as well as in patients with first-degree heart block, diabetes mellitus (due to masked symptoms of hypoglycemia), and pre-existing thyrotoxicosis.

What should I know about interactions with other medicines?

Ateneo (Atenolol) is subject to officially documented interactions that primarily reflect its pharmacological activity and elimination pathway, as described in government regulatory documents.

Contraindicated Combinations

The co-administration of Atenolol is formally contraindicated with certain substances. The intravenous use of Verapamil or Diltiazem is prohibited due to the risk of severe cardiovascular depression, including profound bradycardia and cardiac failure. Furthermore, co-administration with Sultopride is contraindicated because of the heightened risk of ventricular arrhythmias.

Pharmacodynamic and Timing Constraints

Many interactions involve pharmacodynamic reinforcement that increases the effect of blood pressure or heart rate lowering. Concomitant use with cardiac glycosides (e.g., Digoxin) may increase atrioventricular conduction time. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) may reduce the antihypertensive effect of Atenolol. A specific timing rule requires that Atenolol must be withdrawn several days before discontinuing Clonidine to prevent severe rebound hypertension. Concomitant consumption of alcohol may enhance the hypotensive effect.

Exposure and Population Notes

Atenolol undergoes minimal liver metabolism, relying primarily on renal elimination. Consequently, the regulatory label requires that dosage be adjusted in patients with severe renal impairment to mitigate the risk of accumulation.

Mechanism of Action

Atenolol, the active component of Ateneo, exerts its effects through a highly specific mechanism focused on the body's stress response system, specifically targeting beta1-adrenergic receptors.


Targeted Blockade of Cardiac Stress Receptors

Atenolol works by initiating a competitive blockade of the beta1-adrenergic receptors found primarily in the heart. This molecular interaction prevents the excitatory signaling cascade normally triggered by Epinephrine and Norepinephrine, effectively inhibiting the Gs protein pathway and lowering intracellular cAMP levels. This suppression of the sympathetic drive leads to a reduction in the rate of heart contraction (negative chronotropy) and the force of contraction (negative inotropy), which together serve to reduce cardiac output and myocardial oxygen consumption.


Secondary Modulation of the Renin Pathway

The mechanism extends beyond the heart to include modulation of the hormonal Renin-Angiotensin-Aldosterone System (RAAS). Atenolol blocks beta1-receptors located on the juxtaglomerular cells in the kidney, which are responsible for Renin secretion. By suppressing this release, the drug limits a crucial early step in the hormonal cascade that influences fluid balance and peripheral vascular resistance, and results in the modulation of systemic blood pressure over time.

Dosage and Administration Information

How Ateneo is Used: Official Administration Guidelines

This section outlines the methods and dosage rules for administering Atenolol (Ateneo).


Administration and Dosage Forms

Instruction Detail
Approved Routes Primarily Oral (Tablets: 25 mg, 50 mg, 100 mg) for chronic use; Intravenous (IV) Injection for acute, short-term situations.
Standard Dosing Initial dose for hypertension is 25 mg to 50 mg once daily. The typical maintenance range is 50 mg to 100 mg once daily. The maximum daily dose is generally 100 mg.

Key Administration Instructions

Ateneo is usually taken once daily for chronic management, though some regimens (e.g., for angina) may be twice daily. Tablets should be swallowed whole with water and may be divided if they are scored. The drug's absorption may be slightly decreased when taken with food.

When starting or stopping treatment, the dose should be adjusted gradually. The dosage should not be stopped abruptly; instead, it must be tapered down over a period of 7 to 14 days as prescribed. If a dose is missed, patients should skip the missed dose and resume their regular schedule, never taking two doses at once.

Population-Specific Use Rules

Dose adjustments exist for specific groups. Older adults should typically begin therapy with a lower starting dose (25 mg daily). Patients with impaired kidney function (Creatinine Clearance le 35 mL/min/1.73m^2) require dose reduction. Use in children under 18 is not recommended due to a lack of established data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ateneo

The research base for Ateneo involves many clinical studies, primarily Randomized Controlled Trials (RCTs) and comprehensive analyses of multiple trials known as meta-analyses. This body of research helps scientists understand the patterns observed when the agent was studied for various cardiovascular and neurological conditions.


Evidence for Use in Hypertension (High Blood Pressure)

Studies monitored outcomes related to systemic or functional imbalance, such as changes in systolic and diastolic blood pressure over defined time intervals. Research also examined long-term outcomes, including the incidence of major events like stroke and all-cause mortality.

Findings described patterns observed where blood pressure measurements differed when compared to placebo groups. However, when these trials were included in large systematic reviews and meta-analyses, findings were mixed regarding its association with the most critical endpoints. Some research suggests that data related to the incidence of stroke may be lower than that seen with other treatments.

The certainty remains low regarding the optimal use of this agent as a starting treatment for uncomplicated hypertension, particularly in certain populations. Comparative evidence is lacking for some of the newest treatments.


Evidence for Use Following Myocardial Infarction

The evidence for use after a heart attack is derived from early landmark Randomized Controlled Trials. Research examined outcomes related to systemic or functional imbalance, specifically rates of cardiovascular mortality and the occurrence of a subsequent, non-fatal heart attack.

Studies reported how symptoms evolved in the observed populations, and earlier findings were documented for the measured rates of cardiovascular mortality. However, recent observational analyses have described variable associations in patients who have preserved heart function following their acute event.


What is Still Uncertain About Ateneo (Evidence Gaps)

A primary area of ongoing scientific discussion relates to the comparative evaluation of this agent against newer generations of cardiovascular medications, especially concerning the endpoints of stroke and mortality in patients with uncomplicated hypertension. As scientific understanding continues to evolve, inconsistent comparative findings continue to be observed in large meta-analyses, which is a factor in ongoing scientific discussion.

Furthermore, evidence regarding the long-term outcomes for its non-cardiac uses, such as migraine prophylaxis and essential tremor, remains limited due to relatively shorter trial durations.

Key Studies & References

  1. Atenolol: Official Labeling and Regulatory Information
  2. Atenolol: Mechanism of Action, Pharmacokinetics, and Clinical Use in Hypertension and Angina

Frequently Asked Questions (FAQ)

Common questions about Ateneo (FAQ)


Q: What is the elimination half-life of Atenolol, and what does this mean?

A: The official product information indicates that the elimination half-life of Atenolol after oral administration is approximately 6 to 7 hours. The half-life refers to the time it takes for the concentration of the absorbed drug in the body to decrease by half. This indicates that the drug's intended clinical activity, such as lowering blood pressure, is designed to be maintained throughout a full day.


Q: How long does Atenolol take to start working (onset of action)?

A: Official pharmacological data shows that a significant effect of Atenolol is typically noticeable within one hour of taking a single oral dose. The peak (maximal) effect of the medication usually occurs about 2 to 4 hours after ingestion. This information is based on measures of beta-blocking activity in clinical studies.


Q: Does Atenolol interact with grapefruit or grapefruit juice?

A: Core drug labels may not specifically list an interaction with grapefruit or grapefruit juice. However, regulatory warnings often caution about taking this medication with substances that may interfere with drug metabolism. This interference could potentially lead to changes in how much of the medicine is in the blood. Questions regarding dietary concerns are best directed to a healthcare provider.


Q: Does Atenolol interact with common cold or flu medications, and if so, how?

A: Caution is generally advised when taking this medication with other drugs that may affect heart function, such as common cold or flu medicines. Specifically, some of these over-the-counter products may contain sympathomimetic agents (like decongestants), which can increase heart rate or blood pressure. The concomitant use of these medicines is associated with a potential for diminished antihypertensive effect or an increased risk of adverse events, according to official warnings.


Q: Does Atenolol require any special monitoring or tests while I'm taking it?

A: Regulatory information advises that certain patient parameters should be monitored while taking this medication. This typically includes the regular checking of heart rate, blood pressure, and, especially for patients with kidney issues, renal function. The specific tests and frequency of monitoring are determined by the prescribing healthcare professional.


Q: Can I drive or operate machinery while taking Atenolol?

A: Official labeling advises caution regarding driving and operating machinery. Atenolol can cause side effects such as tiredness, dizziness, or lightheadedness, particularly at the start of treatment. The presence of these effects suggests that activities requiring full alertness and coordination may need to be postponed.


Q: What should I do if my side effects from Atenolol do not go away, or if they get worse?

A: Official patient counseling information advises that the occurrence of new, worsening, or severe side effects warrants immediate attention from a healthcare provider. This is particularly important for signs of serious reactions like allergic symptoms, new or worsening chest pain, or sudden and unusual swelling or weight gain.


Q: Is Atenolol a controlled substance?

A: According to regulatory drug facts, Atenolol is classified as a medicine that is not a controlled substance.


Q: Are there specific warnings for people with liver impairment taking Atenolol?

A: Atenolol is minimally metabolized by the liver; however, rare cases of liver injury have been reported in the literature. Regulatory resources note that mild-to-moderate liver enzyme elevations, which are usually temporary and do not cause symptoms, have occurred. The use of this medication by patients with known liver impairment should be reviewed by a healthcare provider.


Q: How long is Atenolol treatment generally prescribed for (chronic or long-term use)?

A: For its approved uses, such as treating high blood pressure or certain heart conditions, treatment with Atenolol is generally intended to be long-term. This commitment to continuous use means the duration of therapy is typically long-term, lasting for many years, as outlined in the treatment plan.


Q: Can I take Atenolol if I have diabetes?

A: The official label includes a warning that Atenolol must be used with caution in patients with diabetes. This is because the medication may mask some of the symptoms of acute low blood sugar (hypoglycemia), most notably the symptom of a fast heart rate. Monitoring blood glucose levels is a factor to consider for diabetic patients using this medicine.


Q: Does Atenolol interact with vitamins or herbal supplements?

A: Regulatory documents suggest caution when combining Atenolol with supplements. Some multivitamins containing minerals may interfere with the drug's absorption, potentially making it less effective. It is important that healthcare providers are aware of all vitamins, herbal products, and supplements being taken, as drug interaction information for these substances may not be fully established.

How should Ateneo be stored and disposed of?

Storage and Handling Requirements

Official labeling requires Atenolol tablets to be stored at a controlled room temperature between 20 C and 25 C (68 F and 77 F). The medication must be protected from freezing, excessive heat, and moisture.

Storage Constraint Requirement
Temperature Controlled Room Temperature
Prohibited Environment Freezing, Excessive Heat/Moisture
Container Rule Keep in a tightly closed container

For safety, the product must be stored out of the reach of children.

Disposal Instructions

Unused or expired Atenolol should be disposed of according to local regulations. The preferred method is using a community drug take-back program. If a program is unavailable, official guidance recommends mixing the tablets with an unappealing substance, placing the mixture in a sealed bag, and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ateneo found in:

A-Z Index: